Testing radiation, chemotherapy, and immunotherapy for early rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of radiation therapy, chemotherapy, and two immunotherapy drugs (which help your immune system fight cancer) as a way to treat early-stage rectal cancer that is low in the rectum. The goal is to see if this approach can shrink or eliminate the cancer so that surgery might be avoided.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 75 years old
- Have a confirmed type of rectal cancer called adenocarcinoma
- Have a tumor that is less than 4 cm across and located very low, within 2 inches of the anal opening
- Have not had any prior treatment for this cancer
- Be in generally good health (able to care for yourself, no serious heart or immune problems)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing whether a short course of radiation combined with chemotherapy and an immunotherapy drug works better than the standard longer radiation and chemotherapy for early-stage rectal cancer that is low in the rectum. The goal is to see if this shorter treatment can help patients avoid surgery or have a better outcome.
This study tests whether combining immunotherapy with a short course of radiation given before surgery can improve outcomes in early-stage rectal cancer. It may help the immune system work better against the tumor before it is removed.
This trial tests a combination of short-course radiation, chemotherapy (CapeOx), and an immunotherapy drug (PD-1 inhibitor) for people with early-stage rectal cancer who have had a local excision but are at high risk of the cancer coming back. The goal is to avoid more extensive surgery while still effectively treating the cancer.
This trial tests a combination of short-course radiation, chemotherapy (capecitabine), and two immunotherapy drugs (PD-1 and CTLA-4 inhibitors) for people with early-stage rectal cancer who want to avoid surgery and keep their anus. The goal is to see if this treatment can shrink the tumor enough to avoid major surgery.
This trial combines a special type of radiation (MRI-guided adaptive radiotherapy) with an immunotherapy drug (PD-1 antibody) and chemotherapy (CAPOX) for locally advanced rectal cancer. The goal is to see if this combination can improve treatment outcomes.
This Phase 2 study tests whether a shorter course of radiation, combined with chemotherapy (CAPOX) and an immunotherapy drug (tislelizumab), can control middle and low rectal cancer. It may also help people who strongly want to keep their anus, if the cancer and overall health fit the study rules.
Hear when a new Early Low Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.